(MENAFN- GlobeNewsWire - Nasdaq) AI diagnostics, genomic sequencing, companion diagnostics and strategic partnerships are accelerating personalized therapies, supported by reimbursement and value-based careDublin, Sept. 30, 2026 (GLOBE NEWSWIRE) -- "Precision Medicine Market Report by Product,Technology, Application, End User, Countries and Companies Analysis 2026-2034" has been added to ResearchAndMarkets.com's offering.
The global precision medicine market is projected to increase from US$ 92.64 billion in 2025 to US$ 243.2 billion by 2034, expanding at a CAGR of 11.32% from 2026 to 2034. Market growth is being driven by the adoption of genomic profiling, AI-powered diagnostics, biomarker-based drug development, next-generation sequencing, and individualized therapies. Supportive healthcare policies, increased research funding, and the transition toward value-based care are also accelerating the commercialization of precision medicine solutions.
Precision Medicine Market Overview
Advances in genomic sequencing, molecular diagnostics, bioinformatics, digital pathology, and artificial intelligence are strengthening precision medicine applications across oncology, rare diseases, pharmacogenomics, immunology, and chronic disease management. Pharmaceutical and biotechnology companies are investing in targeted therapies and companion diagnostics to improve treatment selection, reduce adverse effects, and support better clinical outcomes.
Collaborations among pharmaceutical companies, diagnostic providers, research institutions, software developers, and healthcare organizations are accelerating innovation. The increasing prevalence of cancer and chronic diseases is further supporting demand for molecular profiling and biomarker-driven therapies.
Key Precision Medicine Market Growth Drivers
Artificial Intelligence and Digital Pathology
Artificial intelligence is improving the analysis of genomic, clinical, and histopathological data. AI-enabled platforms can support faster disease detection, patient stratification, and treatment selection, while digital pathology systems facilitate remote analysis and collaboration. These capabilities are particularly valuable in oncology and rare disease diagnostics.
In May 2026, F. Hoffmann-La Roche Ltd. expanded its precision oncology capabilities through the acquisition of AI company Path AI. The transaction strengthened the company's digital pathology and AI-driven companion diagnostics portfolio, reflecting the broader transition toward integrated diagnostic ecosystems.
Expansion of Genomic and NGS-Based Diagnostics
Next-generation sequencing is becoming essential to identifying disease-associated mutations and matching patients with targeted therapies. Lower sequencing costs, improved analytics, supportive regulation, and broader reimbursement coverage are increasing clinical adoption.
In June 2025, QIAGEN collaborated with Incyte to develop an NGS-based diagnostic panel focused on mutant CALR biomarkers for hematologic cancers. The initiative demonstrates the growing role of biomarker-driven treatment selection in precision oncology.
Regional Innovation Ecosystems
Regional precision medicine hubs are connecting research institutions, biotechnology companies, diagnostic laboratories, and healthcare providers. These ecosystems support infrastructure investment, workforce development, clinical translation, and commercialization.
In January 2024, BIOS Health partnered with Kern Venture Group to establish a precision medicine hub in Bakersfield, California. Similar public and private initiatives are improving access to advanced diagnostics and supporting the expansion of personalized healthcare services.
Recent Industry Developments
July 2025: Precision for Medicine expanded its partnership with PathAI to automate digital-pathology analytics and improve the scalability of pathology assessments in global clinical trials. April 2025: Illumina and Tempus AI entered an agreement to develop evidence packages intended to accelerate payer acceptance and reimbursement for sequencing-based diagnostic tests.
Precision Medicine Market Challenges
High implementation costs remain a major barrier, particularly in developing markets. Genomic sequencing platforms, laboratory automation, bioinformatics systems, secure data storage, and specialized personnel require substantial investment. Inconsistent reimbursement policies can also limit patient access and prevent smaller hospitals from incorporating precision medicine into routine clinical workflows.
Data privacy, interoperability, and regulatory compliance present additional challenges. Precision medicine platforms rely on sensitive genomic and clinical information collected from hospitals, laboratories, research databases, and connected devices. Differences in data standards and national regulations complicate cross-border collaboration. Stronger governance frameworks, standardized data formats, secure storage, transparent consent processes, and ethical AI practices will be important for scalable adoption.
Regional Market Outlook
United States: The United States leads the precision medicine market due to its biotechnology ecosystem, research funding, venture capital activity, and early adoption of genomic technologies. The National Institutes of Health All of Us Research Program has enrolled more than 1 million participants, creating a major biomedical dataset for studying genetic diversity and disease patterns.
Germany: Germany is advancing precision medicine through the genomDE initiative, AI-enabled diagnostics, public healthcare investment, and standardized genomic data sharing. Federal health research and digital transformation programs are supporting precision oncology, rare disease diagnosis, and pharmacogenomics while EU data protection requirements govern the secure use of genomic information.
China: China is investing in next-generation sequencing, bioinformatics, AI-enabled diagnostics, and cost-effective genomic testing. Government support, healthcare reforms, and expanding domestic biotechnology capabilities are strengthening applications in oncology, rare diseases, and chronic disease management.
Saudi Arabia: Saudi Arabia is developing its precision medicine capabilities under Vision 2030. The Saudi Genome Program is building national genomic infrastructure to support early disease detection, rare disease identification, precision diagnostics, and personalized therapy development. Investments in digital pathology, AI-driven diagnostics, and precision oncology are positioning the country as an emerging Middle East hub.
Market Segmentation
Product: Consumables, instruments, and services Technology: Big data analytics, bioinformatics, gene sequencing, drug discovery, companion diagnostics, and others Application: Oncology, Central Nervous System (CNS), immunology, respiratory medicine, infections, and others End User: Hospitals and clinics, diagnostic centers, pharma and biotech companies, healthcare IT firms, and others
Consumables are expected to generate recurring demand as sequencing, biomarker testing, and companion diagnostic volumes increase. Bioinformatics will remain a foundational technology for processing multi-omics data and identifying clinically relevant mutations. Immunology applications are expanding through immune profiling, biologics, and targeted immunotherapies, while diagnostic centers are investing in sequencing platforms and AI-enabled systems to support early detection and personalized treatment planning.
Competitive Landscape
Leading precision medicine companies include AstraZeneca plc, Bayer AG, bioMerieux SA, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, Illumina Inc., Laboratory Corporation of America Holdings, Merck KGaA, Novartis AG, Pfizer Inc., Qiagen N.V., Quest Diagnostics Incorporated, and Thermo Fisher Scientific Inc.
Competition is centered on genomic platforms, targeted therapies, companion diagnostics, digital pathology, bioinformatics, and strategic partnerships. Continued investment in clinical evidence, reimbursement support, data infrastructure, and regulatory compliance is expected to shape the global precision medicine market through 2034.
Key Attributes
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood,Senior Press Manager...
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Comments
No comment